THE ARISING · Longevity & Healthspan
Oral Alzheimer's Drug Targeting Brain Immune Cells Passes Early Safety Trial
A pill that reaches the fluid around the brain and acts on the brain's own immune cells has passed its first safety test in people. It has not yet been tested to see whether it helps memory or thinking.
According to Longevity.Technology's report of the study, Muna Therapeutics announced positive Phase 1 results for MNA-001, an oral small-molecule drug that modulates TREM2. This article is based on that report. The paper itself was not reviewed, and nothing here has been checked against it.
TREM2 is a target linked to the brain's immune activity. The report calls the drug a TREM2 modulator and describes soluble TREM2 as a marker of target engagement, meaning a sign the drug is acting on its target.
According to the report, the study was randomized, double-blind and placebocontrolled. It tested single and multiple rising doses in younger volunteers, with an additional elderly group. The report does not give how many people took part or which doses were used.
On safety, the report says there were no serious adverse events. No one stopped taking the drug because of side effects, and most side effects were mild. Phase 1 trials are mainly built to check safety, so this is an early and limited finding.
The company reports that the drug reached substantial levels in cerebrospinal fluid, the fluid that surrounds the brain and spinal cord. Levels in the blood rose in proportion to the dose and were similar in younger and elderly participants, according to the report.
Soluble TREM2 in spinal fluid and blood fell as the dose rose, then reached an apparent plateau at well-tolerated exposures. The report describes this as a marker of target engagement. It is not evidence of a benefit to patients.
The most intriguing result is also the least firm. According to the company, exploratory analyses of spinal fluid after repeated dosing showed that age-associated markers of immune activity in the brain and of nerve-cell stress moved in elderly volunteers toward levels seen in younger participants. The company says this points to biological activity downstream of the target. Exploratory means the analysis was not the main test. These are lab markers, not symptoms, and the report gives no evidence that thinking or memory changed.
This story sits alongside The Arising's October 20 report on a mouse study in which removing brain immune cells restored sleep in Alzheimer's mice. Both concern the brain's immune cells in Alzheimer's disease. They are different work: that was animal research, while this is a human safety trial of a drug, and neither shows a treatment benefit in people.
Muna Therapeutics expects to start a placebo-controlled Phase 2 study in early 2027, using cognitive assessments and biomarkers to evaluate clinical and biological effects. That trial will be the first to show whether the marker shifts come with any change in thinking.